Dolfos Carcifin: Veterinary Product Profile

Dolfos Carcifin is a named branded product for Dogs and cats; manufacturer positioning is kept separate from independent clinical and regulatory evidence.

oral tablets and mini tablets; the official page also displays powder and paste presentation labels that must be checked against the supplied package. Intended species: Dogs and cats.

For the regular tablet, the official product material lists vitamin A 2,000 IU, vitamin D3 200 IU, vitamin E 12 mg, vitamin K 400 micrograms, vitamin C 50 mg, L-arginine 20 mg, zinc 3,000 micrograms, selenium 50 micrograms, and beta-1,3/1,6-glucan 80 mg. It also lists conjugated linoleic acid, mannan oligosaccharides, curcumin, thymol, carvacrol, capsaicin, flavonoids, polyphenols, calcium HMB, safflower oil, Nigella sativa, Rosa canina, and extracts of Curcuma longa, Urtica dioica, Taraxacum officinale, Camellia sinensis, Thymus vulgaris, Echinacea purpurea, and Capsicum annuum. The mini tablet lists proportionally different declared amounts: vitamin A 670 IU, D3 67 IU, E 4 mg, K 135 micrograms, C 17 mg, L-arginine 7 mg, zinc 1,000 micrograms, selenium 16.7 micrograms, and beta-glucan 26.7 mg, with the same named botanical and nutrient matrix.

Dolfos positions Carcifin as nutritional, immune, antioxidant, and condition support for dogs and cats during oncological care. The product name and page context are cancer-adjacent marketing; they do not make the mixture a veterinary antineoplastic medicine or demonstrate that it changes a tumor outcome.

May be discussed only as supportive care within a veterinarian-led plan; it must not replace diagnosis, staging, standard treatment, symptom control, or emergency care.

Define a modest supportive objective, baseline, review date, adverse-event plan, and stopping rule with the veterinarian.

Bring the current label, lot, full ingredient panel, country version, complete diet, medicines, and supplements to the treating veterinarian.

The current manufacturer page and product PDF support identity, species, presentations, and declared composition. No controlled clinical oncology trial of the finished Carcifin product in dogs or cats was located in the official or independent sources reviewed. Evidence concerning individual vitamins, beta-glucans, curcumin, or other botanicals cannot be combined into a product-level conclusion about response, recurrence, or survival.

The formula combines fat-soluble vitamins, minerals, amino acids, botanical extracts, pungent plant constituents, and other supplements. Total vitamin A, D, E, K, zinc, selenium, and overlapping botanicals should be calculated from the complete diet and every supplement. Review bleeding risk, liver or kidney disease, gastrointestinal tolerance, planned anaesthesia, chemotherapy, radiotherapy, targeted treatment, pregnancy, and allergies. The regular and mini compositions must not be treated as interchangeable units.

No universal compatibility conclusion is made. Review the complete label and individualized treatment plan with the veterinarian.

Marketed from Poland as a pet complementary-feed or supplement product. No Polish or EU veterinary-medicinal-product authorisation as an antineoplastic drug was identified. EU feed-marketing rules and the local physical label govern claims and composition; sale in an oncology-support category is not medicine approval.

Poland; European Union

Photograph the exact Polish or export label and record whether the regular, mini, powder, or paste presentation was supplied. Track appetite, vomiting, stool, skin signs, weight, drinking, activity, bruising or bleeding, and prescribed-treatment tolerance. The veterinarian should decide whether chemistry, blood counts, coagulation, or nutrient monitoring is relevant, while objective oncology follow-up remains unchanged.